← Leaderboards
David T Evans
University Of Wisconsin-Madison
$32,138,335
Attributed
$38,300,885
Total exposure
37
Grants
32
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$38,300,885 · 37
By mechanism
R01$25,183,707 · 8
R37$4,843,055 · 1
P51$4,301,272 · 24
P01$3,100,668 · 1
R21$474,523 · 1
K22$270,000 · 1
Top collaborators
- Andres Finzi6 shared
- John C Kappes6 shared
- Edward Barker5 shared
- Susana T Valente5 shared
Most similar at University Of Wisconsin-Madison
Same institution · by research overlap
- Heather B Neuman$3,392,239
- Saverio Vincent Capuano$18,275,423
- Scott M Berry$6,162,635
- Steven A. Ackerman$41,741,762
Others in their field
Top investigators on “Macaca Mulatta”
- Barton F Haynes · Duke University$291,595,855
- Peter Gordon Gillespie · Oregon Health And Science University$83,402,374
- Richard A Gibbs · Baylor College Of Medicine$82,928,769
- Dan H. Barouch · Fred Hutchinson Cancer Center$67,567,747
- David I Watkins · George Washington University$57,087,952
- Rama Rao Amara · Emory University$54,145,017
Research focus
Macaca MulattaVirusCellsInfectionHiv-1MacacaVirus ReplicationAnimalsViralAntibodiesPrimatesReceptorSpecificityNonhuman PrimateVirus DiseasesAnimal ModelSourceVaccinesFundingMutationAffectViral Load ResultResistanceResponse
Grant awards (85)
Evaluation of didehydro-Cortistatin A as a block-and-lock agent for a functional HIV cure in a macaque model$835,797
R01 · FY2025 · AI
Harnessing adaptive NK cell transfer to deplete viral reservoirs$760,984
R01 · FY2025 · AI · contact PI
KIR and MHC Class I Immunogenetics in SIV Infection$731,939
R37 · FY2025 · AI · contact PI
Evaluation of didehydro-Cortistatin A as a block-and-lock agent for a functional HIV cure in a macaque model$847,878
R01 · FY2024 · AI
Tethering lentiviral restriction to Fc-mediated antibody responses$763,634
R01 · FY2024 · AI · contact PI
Harnessing adaptive NK cell transfer to deplete viral reservoirs$760,984
R01 · FY2024 · AI · contact PI
KIR and MHC Class I Immunogenetics in SIV Infection$754,576
R37 · FY2024 · AI · contact PI
Tethering lentiviral restriction to Fc-mediated antibody responses$775,982
R01 · FY2023 · AI · contact PI
Harnessing adaptive NK cell transfer to deplete viral reservoirs$775,114
R01 · FY2023 · AI · contact PI
Assessing ADCC and Fc-mediated Protection against HIV$767,088
R01 · FY2023 · AI · contact PI
KIR and MHC Class I Immunogenetics in SIV Infection$650,079
R37 · FY2023 · AI · contact PI
Assessing ADCC and Fc-mediated Protection against HIV$185,625
R01 · FY2023 · AI · contact PI
Evaluation of didehydro-Cortistatin A as a block-and-lock agent for a functional HIV cure in a macaque model$835,133
R01 · FY2022 · AI
Assessing ADCC and Fc-mediated Protection against HIV$767,578
R01 · FY2022 · AI · contact PI
Harnessing adaptive NK cell transfer to deplete viral reservoirs$751,016
R01 · FY2022 · AI · contact PI
Tethering lentiviral restriction to Fc-mediated antibody responses$707,673
R01 · FY2022 · AI · contact PI
KIR and MHC Class I Immunogenetics in SIV Infection$707,067
R37 · FY2022 · AI · contact PI
Assessing ADCC and Fc-mediated Protection against HIV$764,967
R01 · FY2021 · AI · contact PI
Harnessing adaptive NK cell transfer to deplete viral reservoirs$764,536
R01 · FY2021 · AI · contact PI
KIR and MHC Class I Immunogenetics in SIV Infection$704,172
R37 · FY2021 · AI · contact PI
Tethering lentiviral restriction to Fc-mediated antibody responses$455,834
R01 · FY2021 · AI · contact PI
Evaluation of didehydro-Cortistatin A as a block-and-lock agent for a functional HIV cure in a macaque model$450,949
R01 · FY2021 · AI
Evaluation of didehydro-Cortistatin A as a block-and-lock agent for a functional HIV cure in a macaque model$441,149
R01 · FY2021 · AI
KIR and MHC Class I Immunogenetics in SIV Infection$696,522
R37 · FY2020 · AI · contact PI
Assessing ADCC and Fc-mediated Protection against HIV$656,716
R01 · FY2020 · AI · contact PI
Tethering lentiviral restriction to Fc-mediated antibody responses$454,369
R01 · FY2020 · AI · contact PI
Fcgamma receptor-mediated suppression of immunodeficiency virus replication$765,191
R01 · FY2019 · AI · contact PI
Assessing ADCC and Fc-mediated Protection against HIV$684,196
R01 · FY2019 · AI · contact PI
KIR and MHC Class I Immunogenetics in SIV Infection$598,700
R37 · FY2019 · AI · contact PI
Fcgamma receptor-mediated suppression of immunodeficiency virus replication$765,191
R01 · FY2018 · AI · contact PI
Fcgamma receptor-mediated suppression of immunodeficiency virus replication$765,191
R01 · FY2017 · AI · contact PI
Fcgamma receptor-mediated suppression of immunodeficiency virus replication$766,783
R01 · FY2016 · AI · contact PI
KIR and MHC Class I Immunogenetics in SIV Infection$587,424
R01 · FY2016 · AI · contact PI
Lentiviral Resistance to Tetherin$376,250
R01 · FY2016 · AI · contact PI
Fcgamma receptor-mediated suppression of immunodeficiency virus replication$778,850
R01 · FY2015 · AI · contact PI
KIR and MHC Class I Immunogenetics in SIV Infection$698,799
R01 · FY2015 · AI · contact PI
Lentiviral Resistance to Tetherin$432,385
R01 · FY2015 · AI · contact PI
Lentiviral Resistance to Tetherin$510,239
R01 · FY2014 · AI · contact PI
KIR and MHC Class I Immunogenetics in SIV Infection$422,290
R01 · FY2014 · AI · contact PI
Lentiviral Resistance to Tetherin$33,873
R01 · FY2014 · AI · contact PI
KIR and MHC Class I Immunogenetics in SIV Infection$363,995
R01 · FY2013 · AI · contact PI
Lentiviral Resistance to Tetherin$230,205
R01 · FY2013 · AI · contact PI
Lentiviral Resistance to Tetherin$143,570
R01 · FY2013 · AI · contact PI
KIR and MHC Class I Immunogenetics in SIV Infection$18,209
R01 · FY2013 · AI · contact PI
KIR and MHC Class I Immunogenetics in SIV Infection$592,960
R01 · FY2012 · AI · contact PI
Lentiviral Resistance to Tetherin$437,500
R01 · FY2012 · AI · contact PI
Mechanisms of Lentiviral Resistance to Tetherin$257,648
R21 · FY2011 · AI · contact PI
A NOVEL ASSAY FOR ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY$210,597
P51 · FY2011 · RR · contact PI
MUCOSAL IMMUNITY AND HETEROLOGOUS PROTECTION INDUCED BY SINGLE-CYCLE SIV$210,597
P51 · FY2011 · RR · contact PI
IMMUNIZATION OF MACAQUES WITH SINGLE-CYCLE SIV AS NOVEL AIDS VACCINE APPROACH$210,597
P51 · FY2011 · RR · contact PI
ADAPTATION OF HIV-1 FOR REPLICATION IN RHESUS MACAQUES$210,597
P51 · FY2011 · RR · contact PI
KIR AND MHC CLASS I IMMUNOGENETICS IN SIV INFECTION$210,597
P51 · FY2011 · RR · contact PI
MECHANISMS OF LENTIVIRAL RESISTANCE TO TETHERIN$210,597
P51 · FY2011 · RR · contact PI
Mucosal immunity and heterologous protection induced by single-cycle SIV$767,746
P01 · FY2010 · AI · contact PI
Mechanisms of Lentiviral Resistance to Tetherin$216,875
R21 · FY2010 · AI · contact PI
MECHANISMS OF LENTIVIRAL RESISTANCE TO TETHERIN$202,435
P51 · FY2010 · RR · contact PI
A NOVEL ASSAY FOR ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY$202,435
P51 · FY2010 · RR · contact PI
MUCOSAL IMMUNITY AND HETEROLOGOUS PROTECTION INDUCED BY SINGLE-CYCLE SIV$202,435
P51 · FY2010 · RR · contact PI
IMMUNIZATION OF MACAQUES WITH SINGLE-CYCLE SIV AS NOVEL AIDS VACCINE APPROACH$202,435
P51 · FY2010 · RR · contact PI
Mucosal immunity and heterologous protection induced by single-cycle SIV$811,508
P01 · FY2009 · AI · contact PI
SPECIES-SPECIFICITY OF HIV-1 AND SIV IN OVERCOMING RESTRICTION BY TETHERIN/BST2$206,081
P51 · FY2009 · RR · contact PI
ORAL TRANSMISSION OF SINGLE-CYCLE SIV IN RHESUS MACAQUES$206,081
P51 · FY2009 · RR · contact PI
IMMUNIZATION OF MACAQUES WITH SINGLE-CYCLE SIV AS NOVEL AIDS VACCINE APPROACH$206,081
P51 · FY2009 · RR · contact PI
MUCOSAL IMMUNITY AND HETEROLOGOUS PROTECTION INDUCED BY SINGLE-CYCLE SIV$206,081
P51 · FY2009 · RR · contact PI
Mucosal immunity and heterologous protection induced by single-cycle SIV$777,490
P01 · FY2008 · AI · contact PI
Single-Cycle SIV as a Novel AIDS Vaccine Approach$507,367
R01 · FY2008 · AI · contact PI
SELECTIVE DOWNREGULATION OF RHESUS MACAQUE MHC CLASS I MOLECULES BY NEF$135,175
P51 · FY2008 · RR · contact PI
DYNAMICS OF PRODUCTIVE INFECTION WITH ENVELOPE VARIANTS OF SINGLE-CYCLE SIV$135,175
P51 · FY2008 · RR · contact PI
ORAL TRANSMISSION OF SINGLE-CYCLE SIV IN RHESUS MACAQUES$135,175
P51 · FY2008 · RR · contact PI
IMMUNIZATION OF MACAQUES WITH SINGLE-CYCLE SIV AS NOVEL AIDS VACCINE APPROACH$135,175
P51 · FY2008 · RR · contact PI
Mucosal immunity and heterologous protection induced by single-cycle SIV$743,924
P01 · FY2007 · AI · contact PI
Single-Cycle SIV as a Novel AIDS Vaccine Approach$562,638
R01 · FY2007 · AI · contact PI
DYNAMICS OF PRODUCTIVE INFECTION WITH ENVELOPE VARIANTS OF SINGLE-CYCLE SIV$107,541
P51 · FY2007 · RR · contact PI
SELECTIVE DOWNREGULATION OF RHESUS MACAQUE MHC CLASS I MOLECULES BY NEF$107,541
P51 · FY2007 · RR · contact PI
ORAL TRANSMISSION OF SINGLE-CYCLE SIV IN NEONATAL RHESUS MACAQUES$107,541
P51 · FY2007 · RR · contact PI
IMMUNIZATION OF MACAQUES WITH SINGLE-CYCLE SIV AS NOVEL AIDS VACCINE APPROACH$107,541
P51 · FY2007 · RR · contact PI
Single-Cycle SIV as a Novel AIDS Vaccine Approach$613,112
R01 · FY2006 · AI · contact PI
Single-Cycle SIV as a Novel AIDS Vaccine Approach$604,483
R01 · FY2005 · AI
SINGLE-CYCLE SIV AS A NON-REPLICATING VACCINE STRAIN$228,544
P51 · FY2004 · RR
MUCOSAL PRIMING SIV-SPECIFIC CTL RESPONSES BY SALMONELLA$204,218
P51 · FY2004 · RR
Single-Cycle SIV as a Non-Replicating Vaccine Strain$108,000
K22 · FY2004 · AI
Single-Cycle SIV as a Non-Replicating Vaccine Strain$162,000
K22 · FY2003 · AI
MUCOSAL TRANSMISSION OF SINGLE-CYCLE SIV RECOMBINANTS$48,148
F32 · FY2002 · AI
MUCOSAL TRANSMISSION OF SINGLE-CYCLE SIV RECOMBINANTS$41,996
F32 · FY2001 · AI
MUCOSAL TRANSMISSION OF SINGLE-CYCLE SIV RECOMBINANTS$37,516
F32 · FY2000 · AI